ArticleAging and disease2025
Biological Aging in Combination with Lifestyle Factors in the Blood-Based Methylome: A Biomarker for Colorectal Cancer Susceptibility in African American Women.
Article in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biological Age Should Anchor Age-Related Disease Research.Aging and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
DNA methylation (DNAm)-based estimators of age are highly accurate for biological aging in multiple tissues, but their functional roles remain poorly understood in colorectal cancer (CRC), an age-related disease whose burden is higher in aged African Americans (AAs) than in whites. A greater rate of epigenetic age deviation from chronologic age was observed in AAs' colorectal tissues than in whites', emphasizing AA-specific investigation for epigenetic aging in CRC. Tumor tissue-based DNAm exclusively reflects cancerization, raising a question about its cancer predictability. A prediagnostic peripheral blood leukocyte (PBL)-based DNAm aging marker may thus provide keys to CRC etiology and prevention. From the largest study cohort, we examined 621 AA postmenopausal women 50-79 years old, including a subset of 14 who developed CRC, with their prediagnostic PBL-DNAm. Using three well-known pan-tissue- and blood-based epigenetic clocks, we evaluated correlations with CRC risk and to what degree the cancer risk is modified by lifestyle factors. Epigenetically older age and increased age acceleration were associated with reduced risk for CRC development. Of note, when women had accelerated aging phenotypes at screening, a substantial increased CRC risk was observed in short-term users of exogeneous estrogen, while a profound risk reduction was shown in women eating a healthy diet. Our study contributes to better understanding of the exertion of lifestyle factors in combination with methylome-based aging in colorectal carcinogenesis, detecting a prediagnostic PBL-based aging biomarker that promotes epigenetically targeted strategies tailored to aged AA women at high risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.